IMMUNOPRECISE ANTIBODIES today anounces that Paul Andreola has been appointed as the 6th director of the Company.
IMMUNOPRECISE ANTIBODIES expands its services, anounces settlement agreement with Crossbeta Biosciences BV and announces a dept settlement.
IMMUNOPRECISE ANTIBODIES today announces that ModiQuest® Research is now an OmniAb approved CRO.
IMMUNOPRECISE ANTIBODIES today initiated an antibody development program with an undisclosed, top 15, global pharmaceutical company.
IMMUNOPRECISE ANTIBODIES announced the addition of in-house and custom scFv and VHH phage libraries to their growing service offerings through recent expansion in Europe.
IMMUNOPRECISE ANTIBODIES today reports its financial results for Q1 ended July 31, 2018. The financial statements and related management’s discussion and analysis (“MD&A”) can be viewed on (www.cdrd.ca).